Despite advancements in therapies, men with severe hemophilia still experience debilitating joint bleeds, lowering their quality of life.
New recombinant factor VIII therapy is expected to reduce the number of weekly prophylactic infusions for those with hemophilia A.
CSL Behring's Idelvion® stays in the bloodstream longer, potentially leading to fewer infusions.
Information in this handy guide is broken down into age groups to help nurses educate and inform the children they treat.
Recently published in the journal Blood, a team of researchers reported the successful application of gene therapy in dogs with factor VII (FVII) deficiency.
Merck's Zepatier is the latest fixed-dose oral drug taken daily to treat hepatitis C virus (HCV) infection.
New chapter gives overview of pediatric development in each life stage: infancy, toddler, preschool, school-age and adolescent.
Orange, CA, HTC recognized for excellence in programs and best practices among its staff.
New program for hematology nurses to earn the Registered Nurse-Board Certified (RN-BC) credential.
"Current Trends in the Management of Hemophilia," posted on December 22, 2015, is the latest educational opportunity to become available from Medscape.
eNewsletter Sign Up
Steps for Living
Victory for Women
Donate Your Car